You are not connected
40
4
Par'Immune
Company
|
France
1
followers
Primary tabs
About your organization
Par’Immune is a biopharmaceutical company developing the parasite derived P28GST protein as immunotherapeutic platform in autoimmune and inflammatory diseases.
Besides its protective role in experimental schistosomiasis, the immunomodulatory potential of P28GST has been validated in preclinical models of Inflammatory Bowel Disease and a Phase 2a clinical trial is ongoing in Crohn’s disease.
During 2018, the company will initiate Phase 2 clinical trails both in IBD ans psoriasis.
The company was founded in October 2017 by a well known scientific and business team.
Network (0)
There are no organizations in the network.